

# Hemophilia Management Program



AscellaHealth is proud to deliver a complete hemophilia management program to help the bleeding disorder community. Our program is based on an all-encompassing data analytics interface technology solution that can capture, integrate, and provide unlimited amounts of prescription data and healthcare outcome analytics in a real-time platform. We deliver accurate insights into patient care, provider Rx value, Rx trends, specialty pharmacy performance, dose optimization, treatment paths, and other clinical intervention reports.

With our hemophilia management program, clients enjoy the benefits of having their specialty medical patients in one platform displaying real-time data and analytics.



*AscellaHealth provides a higher level of patient and pharmacy transparency*

# Meaningful Solutions. Better Treatment.



AscellaHealth's specialty pharmacy and infusion network specializes in data, analytics, and cost modeling. We offer real-time front end prescription triage to help patients receive the right care at the right time. Our technology manages and streamlines the specialty Rx prescription process among the physician, patient, specialty pharmacy, and health insurance plan—which means more coordinated care and cost savings.



## HEMOPHILIA MANAGEMENT IN ACTION



### Patient One

55-Year-Old Male on  
RFVIII Product



AscellaHealth Integrates  
Hemophilia Management  
Program



Therapy optimization led  
to savings of  
**\$284,000**  
per year



### Patient Two

25-Year-Old Patient  
Changing Drugs  
in the Middle of Month



AscellaHealth Integrates  
Hemophilia Management  
Program



AscellaHealth discovered  
**\$27,000**  
in drug waste and  
inappropriate therapy




# Specialty Medical Benefit Management: Intravenous Immunoglobulin (IVIG)



Specialty medications take up a larger portion of pharmacy costs every year—a trend that doesn't seem likely to reverse course. Intravenous Immunoglobulin (IVIG) ranks among the top five drug categories in terms of annual spending, which means an innovative management program could drive meaningful savings for payers.

At AscellaHealth, we took what we've learned from our other specialty medical management programs and designed a system to better serve the immune deficiency community. Our IVIG Medication Therapy Management Program focuses on improving patient care outcomes and process improvements.

*Our patient-centered approach supports the missions of the Jeffrey Modell Foundation (JMF) and the Immune Deficiency Foundation (IDF) to inform clinicians, patients, and payers with high-quality information to enhance patient care, clinical outcomes and cost management approaches.*



## Medication Therapy Management

### Prescription for Medical and Pharmacy Benefit Coverage

- Numerous options to ensure IVIG is used appropriately for the right patient in the right setting
- Direct comparison between treatment options via comparable billing procedures and benefit structures
- Removal of unnecessary steps in the supply chain
- Access to better data, leading to more sophisticated analysis and utilization review
- Deploys more of the cost containment toolkit on IVIG medications

### Better Outcomes for Program Clients


- Completely integrated pharmacy and medical specialty drug management
- Clinical programs supporting improved outcomes and cost containment
- Trend management initiatives
- Coordination of nursing services
- Comprehensive patient education and training

# How it Works: Intravenous Immunoglobulin (IVIG)



AscellaHealth's Medical Therapy Management Program provides personalized medical care that is anchored by a dedicated specialty team. Each patient receives a disease-specific care plan that addresses the needs of the patient for their complex neurologic and immunologic conditions. Through our proven methods, you'll discover savings without sacrificing patient quality of care.

AscellaHealth investigates the appropriate site of care for each patient to ensure they are receiving the proper care for their needs without paying too much. Switching from hospital outpatient treatment to in-home treatment could save payers up to 31% per infusion per patient.



We take great care when making formulary adjustments to ensure that patients do not experience a deficiency in care due to a change in treatment. Our data-driven approach to formulary design allows patients to receive proper dosage while still saving payers on costs.

Proper care management can provide substantial economic and clinical benefits. The impact of an IVIG utilization management and dose-optimization program involves comprehensive medical criteria, steps through alternative therapies when clinically appropriate, and pharmacist-led interventions to recommend dose optimization.



We take care to write preauthorization guidelines that prevent wasteful dosage while providing the flexibility that patients and providers need. By implementing smart preauthorization policies, our clients experience less overall spend—while taking steps to mitigate the possibility of adverse events.

*The use of IVIG is increasing as diagnoses of primary immunodeficiencies and neurologic conditions increase, the population ages, and new uses for IVIG are identified. With our IVIG Medical Therapy Management Program, clients stay up-to-date and in the know.*

# Specialty Pharmacy Management: Multiple Sclerosis (MS)



## MS Facts

\$14.7 Billion Market Size  
for MS Drugs

Affects 900,000+  
Americans

Second-Highest Medical  
Cost for Those With  
Chronic Conditions

Most Therapies Exceed  
\$80,000

22+ Drugs Available With  
18 in Development



Multiple Sclerosis is a chronic disease that attacks the central nervous system and affects an estimated 900,000 Americans. Because of this relatively low prevalence, very few managed care organizations have an MS program in effect. And because treatment options for patients remain limited, it's essential to have the right program in place to ensure proper care is received at an honest price.

## Program Features



**Physician Advisory  
Committee**



**Rapid Assessment  
of Symptom  
Severity**



**Access to High-Quality  
Care, Education and  
Resources**



**Clinical  
Pharmacists with  
MSCS**



**Support, Advocacy  
and Wellness  
Programs**



## Contact AscellaHealth Today

To learn more about our MS and other  
Specialty Pharmacy programs.

# Specialty Medical Benefit Management: Hereditary Angioedema (HAE)



Hereditary Angioedema (HAE), a hereditary disorder that affects the immune system, is a rare-ultra-orphan disease, found in about 1 in 10,000 to 1 in 150,000 people worldwide. Most pharmacy benefits management programs are poorly equipped to help such a small population, leaving those patients to face expensive treatments without the right support.

At AscellaHealth, we develop programs specifically aimed at high cost, low population conditions like HAE. We are a Specialty Pharmacy Benefits Management (SPBM) company whose medical Rx infusion program combines clinical expertise with personalized care to ensure patients get the right treatment at a fair cost.

Development of treatment options for HAE is ongoing, with several leading drugs developed in the last 15 years. AscellaHealth tracks the creation and approval of these specialty medications and stays current on the latest research around HAE treatment. Our network of Specialty Pharmacies works with our Specialty Care Coordination Team to obtain the best treatment pathway and obtain the most cost effective regimen needed for treatment. Prudent therapeutic choices, utilization of new treatment paradigms and improvement in availability and accessibility to new therapies will continue to improve the lives of patients with HAE and other orphan diseases.

## Hereditary Angioedema Fast Facts



Often Confused for  
**Allergies or Stomach  
Problems**



Condition Results  
From Low Levels of  
**C1 Inhibitor**

## The High Cost of HAE Treatment

Average of 61  
Specialty Drugs

**\$78,871**

Annual Cost  
(2017)<sup>1</sup>

HAE Treatment &  
Prevention

**\$210,000**

Annual Cost  
(2015)<sup>2</sup>

HAE Treatment &  
Prevention

**\$487,000**

Annual Cost  
(2019))<sup>2</sup>

<sup>1</sup>Source: "Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans: 2017 Year-End Update"

<sup>2</sup>Source: "Hereditary Angioedema: The Economics of Treatment of an Orphan Disease"



**Contact AscellaHealth Today**

To learn more about our HAE and other  
Specialty Pharmacy programs.




1 Treatment Option in  
2005 vs.  
**7 Primary Options  
Since 2009**

# MAKING A DIFFERENCE



Medical Oncology Management from AscellaHealth

## Comprehensive MEDICATION MANAGEMENT



AscellaHealth's medical oncology management program helps payers by reducing their members' drug waste through clinically appropriate interventions, resulting in significant savings for the payer and reductions in member cost share. We target high-cost medications, allowing providers to prescribe a clinically equivalent dose to minimize the amount of drug waste.

## BIOSIMILAR PRODUCT EXAMPLES

Biosimilar adoption is a significant piece of AscellaHealth's medical oncology management program. We support our clients to collaborate on appropriate implementation strategies and establishing best practices—working to understand how best to lower spend while maintaining quality of care. These steps could be the key to increasing biosimilar adoption across the country.

**RITUXIMAB**      **RANIBIZUMAB**  
**INFLIXIMAB**      **AFLIBERCEPT**      **PEGFILGRASTIM**  
**DENOSUMAB**      **BEVACIZUMAB**  
**TRASTUZUMAB**      **PEMETREXED**  
**BORTEZOMIB**

Through innovative initiatives and clinical solutions, AscellaHealth supports clients in reducing their drug spend for highly complex and costly medical benefit drugs while promoting high quality service for their members.

AscellaHealth's  
**CLINICAL  
SOLUTIONS**



UTILIZATION  
MANAGEMENT



SITE OF  
SERVICE



CLINICAL  
MANAGEMENT



BIOSIMILAR  
MANAGEMENT